The global orthostatic hypotension drugs market at a CAGR of almost 8% during the forecast period

Monday, August 26, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Aug. 26, 2019 /PRNewswire/ -- Global Orthostatic Hypotension Drugs Market 2019-2023: About the MarketOrthostatic hypotension is the reduction in systolic blood pressure and can be divided into neurogenic and non-neurogenic forms. This orthostatic hypotension drugs market analysis considers sale from midodrine, northera (droxidopa), fludrocortisone, and other drugs. Our analysis also considers the orthostatic hypotension drugs market in Asia, Europe, North America, and ROW. In 2018, the midodrine segment had a significant share. However, the Northera (droxidopa) segment will grow faster and emerge as the market leader by the end of the forecast period. Northera can activate alpha 1 adrenergic receptors and have numerous physiological effects that may ameliorate the symptoms of nOH. This will contribute to the demand for Northera over the forecast period. Also, our global orthostatic hypotension drugs market report looks at factors such as increasing prevalence of OH in geriatric population, increasing prevalence of chronic diseases associated with high risk of OH, and high market growth opportunities for OH drugs in emerging countries. However, the uncertainties in low diagnosis rate, lack of clinical evidence and unfavorable safety profile of OH drugs, and adoption of non-pharmacological treatment options as first line therapy may hamper the growth of orthostatic hypotension drugs market over the forecast period.

Read the full report: https://www.reportlinker.com/p05807364/?utm_source=PRN 

Global Orthostatic Hypotension Drugs Market: Overview

Increasing prevalence of chronic diseases associated with

high risk of OHThe prevalence of the neurodegenerative diseases, cardiovascular diseases and diabetes is significantly increasing worldwide, raising the risk of OH. It is associated with an underlying autonomic neurologic disorder. Dehydration is also a common condition in people which increases the risk of OH and causing damage to the nerves. This increase in prevalence of chronic diseases associated with high risk of OH will lead to the expansion of the global orthostatic hypotension drugs market at a CAGR of almost 8% during the forecast period.Rise in the use of combination therapy in OH treatmentOH, is a chronic debilitating illness that is difficult to treat in several patients. Single drug therapy might not be adequate in treating OH patients as orthostatic stress varies with circumstances during the day. This has led to the increasing focus on the use of combination therapy in OH treatment. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, global orthostatic hypotension drugs market is moderately fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several orthostatic hypotension drugs manufacturers, that include Amneal Pharmaceuticals Inc., H. Lundbeck AS, Mylan NV, Novartis AG, Pfizer Inc.Also, orthostatic hypotension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Read the full report: https://www.reportlinker.com/p05807364/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-orthostatic-hypotension-drugs-market-at-a-cagr-of-almost-8-during-the-forecast-period-300906776.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store